Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)

被引：0
|
作者：
Gregori, Joaquin Gavila
Miranda, Elena Lopez
Escriva-de-Romani, Santiago
Rodriguez, Begona Jimenez
Novoa, Silvia Antolin
Morales, Luis Fernandez
Calvo, Elena Galve
Cortijo, Lucia Gonzalez
Martorell, Antonia Perello
Ruiz, Julian Lagunar
Santiago, Santiago Gonzalez
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT1-12-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-12-09
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer
    Melichar, Bohuslav
    Studentova, Hana
    Kalabova, Hana
    Vitaskova, Denisa
    IMMUNOTHERAPY, 2014, 6 (07) : 811 - 819
  • [32] Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
    Otoya, Iris
    Valdiviezo, Natalia
    Morante, Zaida
    Calle, Cindy
    Ferreyra, Yomali
    Huarcaya-Chombo, Norma
    Polo-Mendoza, Gabriela
    Castaneda, Carlos
    Vidaurre, Tatiana
    Neciosup, Silvia P.
    Calderon, Monica J.
    Gomez, Henry L.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2024, 2024
  • [33] Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States.
    Manevy, Federico
    Filkauskas, Gabriele
    Levy, Pierre
    Fredriksson, Judy
    Sussell, Jesse
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (03) : 84 - 86
  • [35] Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer
    Luo, Yang
    Li, Wei
    Jiang, Zefei
    Zhang, Qingyuan
    Wang, Liwei
    Mao, Yixiang
    Tjan-Heijnen, Vivianne C. G.
    Im, Seock-Ah
    McConnell, Robin
    Bejarano, Sara
    Fumagalli, Debora
    Bines, Jose
    Wang, Bei
    Garg, Amit
    Kirschbrown, Whitney P.
    Xu, Binghe
    ANTI-CANCER DRUGS, 2019, 30 (08) : 866 - 872
  • [36] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08) : 724 - 734
  • [37] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Kerry Dwan
    Rumona Dickson
    Chris Proudlove
    Yenal Dundar
    PharmacoEconomics, 2015, 33 : 13 - 23
  • [38] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
  • [39] First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
    Araki, Kazuhiro
    Fukada, Ippei
    Yanagi, Hiroyo
    Kobayashi, Kokoro
    Shibayama, Tomoko
    Horii, Rie
    Takahashi, Shunji
    Akiyama, Futoshi
    Ohno, Shinji
    Ito, Yoshinori
    BREAST, 2017, 35 : 78 - 84
  • [40] Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
    Hamizi, Salima
    Freyer, Gilles
    Bakrin, Naoual
    Henin, Emilie
    Mohtaram, Amina
    Le Saux, Olivia
    Falandry, Claire
    ONCOTARGETS AND THERAPY, 2013, 6 : 89 - 94
12345